Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Frontline therapy patterns and outcomes in chronic lymphocytic leukemia: A real-world, multicenter analysis from Latin America.

View Full Paper
Ask AI
Bookmark
Share

Authors

MCMaría Silvana CugliariVIVictoria IrigoinJAJose Alvarez

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows 3-year progression-free survival of 75% for venetoclax, indicating a need for guideline adherence.

Key Points

  • Progression-free survival at 3 years was 51%, varying by treatment regimen among patients with chronic lymphocytic leukemia.
  • Of the 2,133 treated, 42.1% received suboptimal therapies, particularly chlorambucil monotherapy and lymphoma-like regimens.
  • Retrospective analysis across 10 Latin American countries highlights the impact of treatment regimens on survival outcomes.
  • Medical education is critical to improve adherence to evidence-based protocols and reduce use of non-guideline therapies.

Cite This Study

Cugliari et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236db71https://doi.org/10.1182/blood-2025-2775
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1An international view on the current approaches to frontline chronic lymphocytic leukemia therapy2025
  2. 2Baseline clinical characteristics of patients with chronic lymphocytic leukemia (CLL) from 11 Latin American countries: A real-world registry analysis2025
  3. 3Discovering the epidemiology, treatment patterns, and outcomes of chronic lymphocytic leukemia: A retrospective multicenter cohort study2025
  4. 4First-line venetoclax-based regimens versus chemoimmunotherapy in chronic lymphocytic leukemia: A real-world analysis from the brazilian CLL registry2025
  5. 5Real-world treatment and outcomes of Mantle Cell Lymphoma in Latin America: A multinational cohort analysis2025